BerGenBio

BERGENBIO TO PRESENT AT ABG SUNDAL COLLIER LIFE SCIENCE SUMMIT

Bergen, Norway, 16 May 2022 - BerGenBio ASA (OSE:BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL inhibitors for severe

unmet medical needs, is pleased to announce that CEO Martin Olin will be

presenting at the ABG Sundal Collier Life Science Summit taking place on

Wednesday 18 May at 11:30 CEST.

The presentation slides will be made available on the Company's website in the

Investors section shortly after the presentation.

-Ends-

Contacts

Martin Olin CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA

+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications

+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate bemcentinib a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit?www.bergenbio.com

AI Terminal